This company listing is no longer active
BVX Stock Overview
A biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BiVictriX Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.14 |
| 52 Week Low | UK£0.07 |
| Beta | -0.73 |
| 1 Month Change | -23.08% |
| 3 Month Change | -18.37% |
| 1 Year Change | -28.57% |
| 3 Year Change | -50.00% |
| 5 Year Change | n/a |
| Change since IPO | -60.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| BVX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 33.3% | 5.7% | 0.7% |
| 1Y | -28.6% | -19.6% | 8.4% |
Return vs Industry: BVX underperformed the UK Biotechs industry which returned -21.4% over the past year.
Return vs Market: BVX underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| BVX volatility | |
|---|---|
| BVX Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BVX's share price has been volatile over the past 3 months.
Volatility Over Time: BVX's weekly volatility has increased from 7% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 17 | Tiffany Thorn | www.bivictrix.com |
BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia.
BiVictriX Therapeutics plc Fundamentals Summary
| BVX fundamental statistics | |
|---|---|
| Market cap | UK£8.25m |
| Earnings (TTM) | -UK£2.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs BVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£2.67m |
| Earnings | -UK£2.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/10 01:47 |
| End of Day Share Price | 2024/09/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BiVictriX Therapeutics plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Mitchell | Panmure Liberum Historic (Panmure Gordon) |